Emerging therapeutic strategies for overcoming proteasome inhibitor resistance

Advances in Cancer Research

Volumn 127, Issue 1, 2015, Pages 191-226

  Dolloff, Nathan G ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BORTEZOMIB; BROMODOMAIN INHIBITOR; CANFOSFAMIDE; CARFILZOMIB; DARATUMUMAB; DEXAMETHASONE; DISULFIRAM; EZATIOSTAT; HISTONE DEACETYLASE INHIBITOR; HYDROXYCHLOROQUINE; IMATINIB; INTERLEUKIN 6; IXAZOMIB; LENALIDOMIDE; MONOCLONAL ANTIBODY; OBATOCLAX; OPROZOMIB; PANOBINOSTAT; PROTEASOME INHIBITOR; RICOLINOSTAT; SALINOSPORAMIDE A; SILTUXIMAB; SORAFENIB; STAT3 PROTEIN; TOCILIZUMAB; TUBACIN; VENETOCLAX; VORINOSTAT; ANTINEOPLASTIC AGENT; PROTEASOME; PROTEIN MDM2;

ARTICLE; AUTOPHAGY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; DRUG POTENTIATION; GENE MUTATION; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PLASMA CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; UPREGULATION; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; ADAPTATION; APOPTOSIS; DRUG MECHANISM; EPIGENETICS; PLEIOTROPY; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BORTEZOMIB; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIPLE MYELOMA; PROTEASOME INHIBITORS;

EID: 84940202166     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/bs.acr.2015.03.002     Document Type: Chapter

References (193)

1. Adams, J. (2004). The proteasome: A suitable antineoplastic target. Nature Reviews. Cancer, 4, 349-360.
2. Adler, V., Yin, Z., Fuchs, S. Y., Benezra, M., Rosario, L., Tew, K. D., et al. (1999). Regulation of JNK signaling by GSTp. The EMBO Journal, 18, 1321-1334.
3. Affer, M., Chesi, M., Chen, W. D., Keats, J. J., Demchenko, Y. N., Tamizhmani, K., et al. (2014). Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia, 28, 1725-1735.
4. Alas, S., & Bonavida, B. (2003). Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clinical Cancer Research, 9, 316-326.
5. Allen, S. (2007). The Velcade story. Retrieved from: http://www.boston.com/business/healthcare/articles/(2007)/05/06/the_velcade_story/?page1/4full.
6. Badros, A., Burger, A. M., Philip, S., Niesvizky, R., Kolla, S. S., Goloubeva, O., et al. (2009). Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clinical Cancer Research, 15, 5250-5257.
7. Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., et al. (1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science, 244, 217-221.
8. Balsas, P., Galán-Malo, P., Marzo, I., & Naval, J. (2012). Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy. Leukemia Research, 36, 212-218.
9. Balsas, P., López-Royuela, N., Galán-Malo, P., Anel, A., Marzo, I., & Naval, J. (2009). Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochemical Pharmacology, 77, 804-812.
10. Bennaceur-Griscelli, A., Bosq, J., Koscielny, S., Lefrère, F., Turhan, A., Brousse, N., et al. (2004). High level of glutathione-S-transferase pi expression in mantle cell lymphomas. Clinical Cancer Research, 10, 3029-3034.
11. Berenson, J. R., Matous, J., Swift, R. A., Mapes, R., Morrison, B., & Yeh, H. S. (2007). A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clinical Cancer Research, 13, 1762-1768.
12. Bergsagel, P. L. (2014). Where we were, where we are, where we are going: Progress in multiple myeloma. American Society of Clinical Oncology Educational Book/ASCO, 199-203.
13. Bergsagel, D. E., Sprague, C. C., Austin, C., & Griffith, K. M. (1962). Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). Cancer Chemotherapy Reports, 21, 87-99.
14. Bharti, A. C., Shishodia, S., Reuben, J. M., Weber, D., Alexanian, R., Raj-Vadhan, S., et al. (2004). Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood, 103, 3175-3184.
15. Bhattacharya, S., Ray, R. M., & Johnson, L. R. (2005). STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. The Biochemical Journal, 392, 335-344.
16. Bhattacharyya, S., Yu, H., Mim, C., & Matouschek, A. (2014). Regulated protein turnover: Snapshots of the proteasome in action. Nature Reviews. Molecular Cell Biology, 15, 122-133.
17. Boya, P., Gonzalez-Polo, R. A., Poncet, D., Andreau, K., Vieira, H. L., Roumier, T., et al. (2003). Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene, 22, 3927-3936.
18. Boyd, K. D., Ross, F. M., Tapper, W. J., Chiecchio, L., Dagrada, G., Konn, Z. J., et al. (2011). The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes, Chromosomes & Cancer, 50, 765-774.
19. Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., et al. (2002). High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood, 99, 3472-3475.
20. Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., et al. (1999). Stat3 as an oncogene. Cell, 98, 295-303.
21. Campbell, R. A., Sanchez, E., Steinberg, J. A., Baritaki, S., Gordon, M., Wang, C., et al. (2007). Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. British Journal of Haematology, 138, 467-478.
22. Canestraro, M., Galimberti, S., Savli, H., Palumbo, G. A., Tibullo, D., Nagy, B., et al. (2010). Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genetics and Cytogenetics, 199, 110-120.
23. Carpenter, R. L., & Lo, H. W. (2014). STAT3 target genes relevant to human cancers. Cancers, 6, 897-925.
24. Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., et al. (1999). Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 10, 105-115.
25. Cenci, S., & Sitia, R. (2007). Managing and exploiting stress in the antibody factory. FEBS Letters, 581, 3652-3657.
26. Chaidos, A., Caputo, V., Gouvedenou, K., Liu, B., Marigo, I., Chaudhry, M. S., et al. (2014). Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood, 123, 697-705.
27. Chen, S., Blank, J. L., Peters, T., Liu, X. J., Rappoli, D. M., Pickard, M. D., et al. (2010). Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Research, 70, 4318-4326.
28. Chen, M. H., Qi, C. X. Y., Saha, M. N., & Chang, H. (2012). p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide. American Journal of Clinical Pathology, 137, 208-212.
29. Chen, K. F., Tai, W. T., Hsu, C. Y., Huang, J. W., Liu, C. Y., Chen, P. J., et al. (2012). Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity. European Journal of Medicinal Chemistry, 55, 220-227.
30. Chen, K. F., Tai, W. T., Huang, J. W., Hsu, C. Y., Chen, W. L., Cheng, A. L., et al. (2011). Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. European Journal of Medicinal Chemistry, 46, 2845-2851.
31. Chen, S., Zhang, Y., Zhou, L., Leng, Y., Lin, H., Kmieciak, M., et al. (2014). A Bimtargeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood, 124, 2687-2697.
32. Chène, P. (2003). Inhibiting the p53-MDM2 interaction: An important target for cancer therapy. Nature Reviews. Cancer, 3, 102-109.
33. Chesi, M., Matthews, G. M., Garbitt, V. M., Palmer, S. E., Shortt, J., Lefebure, M., et al. (2012). Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood, 120, 376-385.
34. Chng, W. J., Price-Troska, T., Gonzalez-Paz, N., Van Wier, S., Jacobus, S., Blood, E., et al. (2007). Clinical significance of TP53 mutation in myeloma. Leukemia, 21, 582-584.
35. Collins, S. M., Bakan, C. E., Swartzel, G. D., Hofmeister, C. C., Efebera, Y. A., Kwon, H., et al. (2013). Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: Evidence for augmented NK cell function complementing ADCC. Cancer Immunology, Immunotherapy, 62, 1841-1849.
36. Cullinan, S. B., & Diehl, J. A. (2004). PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. The Journal of Biological Chemistry, 279(2010), 8-17.
37. Dalton, W. S., & Jove, R. (1999). Drug resistance in multiple myeloma: Approaches to circumvention. Seminars in Oncology, 26(5 Suppl. 13), 23-27.
38. de St Groth, S. F. (1983). Automated production of monoclonal antibodies in a cytostat. Journal of Immunological Methods, 57, 121-136.
39. de Wilt, L. H., Jansen, G., Assaraf, Y. G., van Meerloo, J., Cloos, J., Schimmer, A. D., et al. (2012). Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. Biochemical Pharmacology, 83, 207-217.
40. Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P.B., Shi, J., Jacobs, H. M., et al. (2011). BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell, 146, 904-917.
41. Demasi, M., Hand, A., Ohara, E., Oliveira, C. L., Bicev, R. N., Bertoncini, C. A., et al. (2014). 20S proteasome activity is modified via S-glutathionylation based on intracellular redox status of the yeast Saccharomyces cerevisiae: Implications for the degradation of oxidized proteins. Archives of Biochemistry and Biophysics, 557, 65-71.
42. Demasi, M., Netto, L. E., Silva, G. M., Hand, A., de Oliveira, C. L., Bicev, R. N., et al. (2013). Redox regulation of the proteasome via S-glutathionylation. Redox Biology, 2, 44-51.
43. Demasi, M., Shringarpure, R., & Davies, K. J. (2001). Glutathiolation of the proteasome is enhanced by proteolytic inhibitors. Archives of Biochemistry and Biophysics, 389, 254-263.
44. Derenne, S., Monia, B., Dean, N. M., Taylor, J. K., Rapp, M. J., Harousseau, J. L., et al. (2002). Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood, 100, 194-199.
45. Dimopoulos, M., Siegel, D. S., Lonial, S., Qi, J., Hajek, R., Facon, T., et al. (2013). Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): A multicentre, randomised, double-blind study. The Lancet Oncology, 14, 1129-1140.
46. Doi, K., Li, R., Sung, S. S., Wu, H., Liu, Y., Manieri, W., et al. (2012). Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. The Journal of Biological Chemistry, 287, 10224-10235.
47. El-Deiry, W. S. (1998). Regulation of p53 downstream genes. Seminars in Cancer Biology, 8, 345-357.
48. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., et al. (2010). Selective inhibition of BET bromodomains. Nature, 468, 1067-1073.
49. Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M. M., Kyle, R. A., et al. (2003). Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood, 101, 4569-4575.
50. Franke, N. E., Niewerth, D., Assaraf, Y. G., van Meerloo, J., Vojtekova, K., van Zantwijk, C. H., et al. (2012). Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. Leukemia, 26, 757-768.
51. Fribley, A., Zeng, Q., &Wang, C. Y. (2004). Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Molecular and Cellular Biology, 24, 9695-9704.
52. Fuhrmann, G., Rosenberger, G., Grusch, M., Klein, N., Hofmann, J., & Krupitza, G. (1999). The MYC dualism in growth and death. Mutation Research, 437, 205-217.
53. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., et al. (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, 876-880.
54. Groll, M., Berkers, C. R., Ploegh, H. L., & Ovaa, H. (2006). Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure, 14, 451-456.
55. Grune, T., Catalgol, B., Licht, A., Ermak, G., Pickering, A. M., Ngo, J. K., et al. (2011). HSP70 mediates dissociation and reassociation of the 26S proteasome during adaptation to oxidative stress. Free Radical Biology & Medicine, 51, 1355-1364.
56. Gu, D., Wang, S., Kuiatse, I., Wang, H., He, J., Dai, Y., et al. (2014). Inhibition of the MDM2 E3 ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. PLoS One, 9, e103015.
57. Harding, H. P., Zhang, Y., Zeng, H., Novoa, I., Lu, P. D., Calfon, M., et al. (2003). An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Molecular Cell, 11, 619-633.
58. He, X., Yang, K., Chen, P., Liu, B., Zhang, Y., Wang, F., et al. (2014). Arsenic trioxidebased therapy in relapsed/refractory multiple myeloma patients: A meta-analysis and systematic review. OncoTargets and Therapy, 7, 1593-1599.
59. Hendershot, L. M., & Sitia, R. (2005). Immunoglobulin assembly and secretion. In T. Honjo, F. W. Alt, & M. Neuberger (Eds.), Molecular biology of B cells (pp. 261-273): Amsterdam, The Netherlands: Elsevier Science.
60. Hideshima, T., Bradner, J. E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S. L., et al. (2005). Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 102, 8567-8572.
61. Hideshima, T., Mitsiades, C., Akiyama, M., Hayashi, T., Chauhan, D., Richardson, P., et al. (2003). Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 101, 1530-1534.
62. Hideshima, T., Richardson, P. G., & Anderson, K. C. (2011). Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Molecular Cancer Therapeutics, 10, 2034-2042.
63. Hoang, B., Benavides, A., Shi, Y., Frost, P., & Lichtenstein, A. (2009). Effect of autophagy on multiple myeloma cell viability. Molecular Cancer Therapeutics, 8, 1974-1984.
64. Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991). p53 mutations in human cancers. Science, 253, 49-53.
65. Hong, D. S., Younes, A., Fayad, L., Fowler, N. H., Hagemeister, F. B., Mistry, R., et al. (2013). A phase I study of ISIS 481464 (AZD9150), a first-in-human, first-in-class, antisense oligonucleotide inhibitor of STAT3, in patients with advanced cancers. Journal of Clinical Oncology, 31, 8523.
66. Hsi, E. D., Steinle, R., Balasa, B., Szmania, S., Draksharapu, A., Shum, B. P., et al. (2008). CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clinical Cancer Research, 14, 2775-2784.
67. Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P. G., et al. (2004). A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British Journal of Haematology, 127, 165-172.
68. Jagannathan, S., Malek, E., Vallabhapurapu, S., Vallabhapurapu, S., & Driscoll, J. J. (2014). Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells. Oncotarget, 5, 12358-12370.
69. Jakubowiak, A. J., Benson, D. M., Bensinger, W., Siegel, D. S., Zimmerman, T. M., Mohrbacher, A., et al. (2012). Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. Journal of Clinical Oncology, 30, 1960-1965.
70. Jin, L., Tabe, Y., Kojima, K., Zhou, Y., Pittaluga, S., Konopleva, M., et al. (2010). MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Letters, 299, 161-170.
71. Johnson-Farley, N., 1, Veliz, J., Bhagavathi, S., & Bertino, J. R. (2015). ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in "double hit" lymphoma cells. Leukemia & Lymphoma, 1-7.
72. Jung, H. J., Chen, Z., & McCarty, N. (2012). Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma. American Journal of Hematology, 87, 1057-1064.
73. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., et al. (1988). Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature, 332, 83-85.
74. Kharaziha, P., De Raeve, H., Fristedt, C., Li, Q., Gruber, A., Johnsson, P., et al. (2012). Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model. Cancer Research, 72, 5348-5362.
75. Kiziltepe, T., Hideshima, T., Ishitsuka, K., Ocio, E. M., Raje, N., Catley, L., et al. (2007). JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood, 110, 709-718.
76. Klein, B., Zhang, X. G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., et al. (1989). Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood, 73, 517-526.
77. Kuehl, W. M., & Bergsagel, P. L. (2012). MYC addiction: A potential therapeutic target in MM. Blood, 120, 2351-2352.
78. Kumar, S. K., Jett, J., Marks, R., Richardson, R., Quevedo, F., Moynihan, T., et al. (2013). Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies. Investigational New Drugs, 31, 1201-1206.
79. Lane, D. (1992). Cancer. p53, guardian of the genome. Nature, 358, 15-16.
80. Laubach, J. P., Tai, Y. T., Richardson, P. G., & Anderson, K. C. (2014). Daratumumab granted breakthrough drug status. Expert Opinion on Investigational Drugs, 23, 445-452.
81. Li, J., Favata, M., Kelley, J. A., Caulder, E., Thomas, B., Wen, X., et al. (2010). INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia, 12, 28-38.
82. Lichter, D. I., Danaee, H., Pickard, M. D., Tayber, O., Sintchak, M., Shi, H., et al. (2012). Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood, 120, 4513-4516.
83. Lin, P., Owens, R., Tricot, G., &Wilson, C. S. (2004). Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. American Journal of Clinical Pathology, 121, 482-488.
84. Ling, Y. H., Liebes, L., Zou, Y., & Perez-Soler, R. (2003). Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. The Journal of Biological Chemistry, 278, 33714-33723.
85. Liu, H., & May, K. (2012). Disulfide bond structures of IgG molecules: Structural variations, chemical modifications and possible impacts to stability and biological function. MAbs, 4, 17-23.
86. Lodé, L., Eveillard, M., Trichet, V., Soussi, T., Wuillème, S., Richebourg, S., et al. (2010). Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica, 95, 1973-1976.
87. Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., et al. (2013). Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell, 153, 320-334.
88. L€u, S., Chen, Z., Yang, J., Chen, L., Gong, S., Zhou, H., et al. (2008). Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Experimental Hematology, 36, 1278-1284.
89. L€u, S., Yang, J., Chen, Z., Gong, S., Zhou, H., Xu, X., et al. (2009). Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line. Experimental Hematology, 37, 831-837.
90. L€u, S., Yang, J., Song, X., Gong, S., Zhou, H., Guo, L., et al. (2008). Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. The Journal of Pharmacology and Experimental Therapeutics, 326, 423-431.
91. L€utticken, C., Wegenka, U. M., Yuan, J., Buschmann, J., Schindler, C., Ziemiecki, A., et al. (1994). Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science, 263, 89-92.
92. Maiso, P., Carvajal-Vergara, X., Ocio, E. M., López-Pérez, R., Mateo, G., Gutiérrez, N., et al. (2006). The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Research, 66, 5781-5789.
93. Meek, D. W.,& Anderson, C. W. (2009). Posttranslational modification of p53: Cooperative integrators of function. Cold Spring Harbor Perspectives in Biology, 1, a000950.
94. Merten, O. W., Keller, H., Cabanie, L., Litwin, J., & Flamand, B. (1989). Development of a serum-free medium for hybridoma fermentor cultures. In R. E. Spier, J. R. Griffiths, J. Stephenné, & P. J. Crooy (Eds.), Advances in animal cell biology and technology for bioprocesses (pp. 263-268). United Kingdom: Butterworths.
95. Mitsiades, N., Mitsiades, C. S., Poulaki, V., Anderson, K. C., & Treon, S. P. (2001). Concepts in the use of TRAIL/Apo2L: An emerging biotherapy for myeloma and other neoplasias. Expert Opinion on Investigational Drugs, 10, 1521-1530.
96. Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., et al. (2002). Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proceedings of the National Academy of Sciences of the United States of America, 99, 14374-14379.
97. Mitsiades, C. S., Treon, S. P., Mitsiades, N., Shima, Y., Richardson, P., Schlossman, R., et al. (2001). TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications. Blood, 98, 795-804.
98. Monaghan, K. A., Khong, T., Burns, C. J., & Spencer, A. (2011). The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells. Leukemia, 25, 1891-1899.
99. Moriya, S., Che, X. F., Komatsu, S., Abe, A., Kawaguchi, T., Gotoh, A., et al. (2013). Macrolide antibiotics block autophagy flux and sensitize to bortezomib via endoplasmic reticulum stress-mediated CHOP induction in myeloma cells. International Journal of Oncology, 42, 1541-1550.
100. Nawrocki, S. T., Carew, J. S., Maclean, K. H., Courage, J. F., Huang, P., Houghton, J. A., et al. (2008). Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood, 112, 2917-2926.
101. Nencioni, A., Hua, F., Dillon, C. P., Yokoo, R., Scheiermann, C., Cardone, M. H., et al. (2005). Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood, 105, 3255-3262.
102. Nerini-Molteni, S., Ferrarini, M., Cozza, S., Caligaris-Cappio, F., & Sitia, R. (2008). Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. British Journal of Haematology, 141, 494-503.
103. Nguyen, M., Marcellus, R. C., Roulston, A., Watson, M., Serfass, L., Murthy Madiraju, S. R., et al. (2007). Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 104, 19512-19517.
104. Nikiforov, M. A., Riblett, M., Tang, W. H., Gratchouck, V., Zhuang, D., Fernandez, Y., et al. (2007). Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proceedings of the National Academy of Sciences of the United States of America, 104, 19488-19493.
105. Oerlemans, R., Franke, N. E., Assaraf, Y. G., Cloos, J., van Zantwijk, I., Berkers, C. R., et al. (2008). Molecular basis of bortezomib resistance: Proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood, 112, 2489-2499.
106. Ooi, M., Hayden, P. J., Kotoula, V., McMillin, D. W., Charalambous, E., Daskalaki, E., et al. (2009). Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clinical Cancer Research, 15, 7153-7160.
107. Orlowski, R. Z., Gercheva, L., Williams, C., Sutherland, H., Robak, T., Masszi, T., et al. (2015). A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. American Journal of Hematology, 90, 42-49.
108. Orlowski, R. Z., Stinchcombe, T. E., Mitchell, B. S., Shea, T. C., Baldwin, A. S., Stahl, S., et al. (2002). Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. Journal of Clinical Oncology, 20, 4420-4427.
109. Paoluzzi, L., Gonen, M., Bhagat, G., Furman, R. R., Gardner, J. R., Scotto, L., et al. (2008). The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood, 112, 2906-2916.
110. Pei, X. Y., Dai, Y., & Grant, S. (2003). The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia, 17, 2036-2045.
111. Pei, X. Y., Dai, Y., & Grant, S. (2004). Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clinical Cancer Research, 10, 3839-3852.
112. Pérez-Galán, P., Roué, G., López-Guerra, M., Nguyen, M., Villamor, N., Montserrat, E., et al. (2008). BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia, 22, 1712-1720.
113. Pérez-Galán, P., Roué, G., Villamor, N., Campo, E., & Colomer, D. (2007). The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood, 109, 4441-4449.
114. Pérez-Galán, P., Roué, G., Villamor, N., Montserrat, E., Campo, E., & Colomer, D. (2006). The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood, 107, 257-264.
115. Petrini, M., Di Simone, D., Favati, A., Mattii, L., Valentini, P., & Grassi, B. (1995). GST-pi and P-170 co-expression in multiple myeloma. British Journal of Haematology, 90, 393-397.
116. Podar, K., Gouill, S. L., Zhang, J., Opferman, J. T., Zorn, E., Tai, Y. T., et al. (2008). A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Oncogene, 27, 721-731.
117. Politou, M., Karadimitris, A., Terpos, E., Kotsianidis, I., Apperley, J. F., & Rahemtulla, A. (2006). No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib. Leukemia Research, 30, 240-241.
118. Preudhomme, C., Facon, T., Zandecki, M., Vanrumbeke, M., Lai{dotless}, J. L., Nataf, E., et al. (1992). Rare occurrence of P53 gene mutations in multiple myeloma. British Journal of Haematology, 81, 440-443.
119. Puthier, D., Bataille, R., & Amiot, M. (1999). IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. European Journal of Immunology, 29, 3945-3950.
120. Raje, N., Hari, P. N., Vogl, D. T., Jagannath, S., Orlowski, R. Z., Supko, J. G., et al. (2012). Rocilinostat (ACY-1215), a selective HDAC6 inhibitor, alone and in combination with bortezomib in multiple myeloma: Preliminary results from the first-in-humans phase I/II study. In ASH annual meeting, Abstract 4061.
121. Ramakrishnan, V., Timm, M., Haug, J. L., Kimlinger, T. K., Wellik, L. E., Witzig, T. E., et al. (2010). Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common antimyeloma drugs. Oncogene, 29, 1190-1202.
122. Reinheckel, T., Ullrich, O., Sitte, N., & Grune, T. (2000). Differential impairment of 20S and 26S proteasome activities in human hematopoietic K562 cells during oxidative stress. Archives of Biochemistry and Biophysics, 377, 65-68.
123. Ri, M., Iida, S., Nakashima, T., Miyazaki, H., Mori, F., Ito, A., et al. (2010). Bortezomibresistant myeloma cell lines: A role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia, 24, 1506-1512.
124. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., et al. (2003). A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine, 348, 2609-2617.
125. Roche-Lestienne, C., Soenen-Cornu, V., Grardel-Duflos, N., Lai{dotless}, J. L., Philippe, N., Facon, T., et al. (2002). Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood, 100, 1014-1018.
126. Rolland, D., Raharijaona, M., Barbarat, A., Houlgatte, R., & Thieblemont, C. (2010). Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin. Anticancer Research, 30, 3951-3957.
127. Roumiantsev, S., Shah, N. P., Gorre, M. E., Nicoll, J., Brasher, B. B., Sawyers, C. L., et al. (2002). Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proceedings of the National Academy of Sciences of the United States of America, 99, 10700-10705.
128. R€uckrich, T., Kraus, M., Gogel, J., Beck, A., Ovaa, H., Verdoes, M., et al. (2009). Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia, 23, 1098-1105.
129. Saha, M., Jiang, H., Jayakar, J., Reece, D., Branch, D. R., & Chang, H. (2010). MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biology & Therapy, 9, 936-944.
130. Salem, K., McCormick, M. L., Wendlandt, E., Zhan, F., & Goel, A. (2015). Copper-zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma. Redox Biology, 4C, 23-33.
131. Sanchez-Serrano, I. (2005). Translational research in the development of bortezomib: A core model. Discovery Medicine, 5, 527-533.
132. Sánchez-Serrano, I. (2006). Success in translational research: Lessons from the development of bortezomib. Nature Reviews. Drug Discovery, 5, 107-114.
133. San-Miguel, J., Bladé, J., Shpilberg, O., Grosicki, S., Maloisel, F., Min, C. K., et al. (2014). Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood, 123, 4136-4142.
134. San-Miguel, J. F., Hungria, V. T., Yoon, S. S., Beksac, M., Dimopoulos, M. A., Elghandour, A., et al. (2014). Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial. The Lancet Oncology, 15, 1195-1206.
135. San-Miguel, J. F., Richardson, P. G., G€unther, A., Sezer, O., Siegel, D., Bladé, J., et al. (2013). Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. Journal of Clinical Oncology, 31, 3696-3703.
136. Santo, L., Hideshima, T., Kung, A. L., Tseng, J. C., Tamang, D., Yang, M., et al. (2012). Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood, 119, 2579-2589.
137. Schneider, Y. J. (1989). Optimization of hybridoma growth and monoclonal antibody secretion in a chemically defined, serum-and protein-free culture medium. Journal of Immunological Methods, 116, 65-77.
138. Scuto, A., Krejci, P., Popplewell, L., Wu, J., Wang, Y., Kujawski, M., et al. (2011). The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia, 25, 538-550.
139. Sekiguchi, N., Ootsubo, K., Wagatsuma, M., Midorikawa, K., Nagata, A., Noto, S., et al. (2014). The impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy. International Journal of Hematology, 99, 288-295.
140. Shacter, E. (1987). Serum-free medium for growth factor-dependent and -independent plasmacytomas and hybridomas. Journal of Immunological Methods, 99, 259-270.
141. Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., et al. (2002). Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2, 117-125.
142. Sharma, M., Khan, H., Thall, P. F., Orlowski, R. Z., Bassett, R. L., Jr., Shah, N., et al. (2012). A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer, 118, 2507-2515.
143. Shi, L., Wang, S., Zangari, M., Xu, H., Cao, T. M., Xu, C., et al. (2010). Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget, 1, 22-33.
144. Shieh, S. Y., 1, Ikeda, M., Taya, Y., & Prives, C. (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell, 91, 325-334.
145. Shimizu, Y., & Hendershot, L. M. (2009). Oxidative folding: Cellular strategies for dealing with the resultant equimolar production of reactive oxygen species. Antioxidants & Redox Signaling, 11, 2317-2331.
146. Shou, Y., Martelli, M. L., Gabrea, A., Qi, Y., Brents, L. A., Roschke, A., et al. (2000). Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 97, 228-233.
147. Shuqing, L., Jianmin, Y., Chongmei, H., Hui, C., & Wang, J. (2011). Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen. Experimental Hematology, 39, 1117-1118.
148. Siegel, M. B., Davare, M. A., Liu, S. Q., Spurgeon, S. E., Loriaux, M. M., Druker, B. J., et al. (2014). 4702 the bromodomain inhibitor CPI203 demonstrates preclinical synergistic activity with bortezomib in drug resistant myeloma. In ASH annual meeting, Abstract 4702.
149. Siegel, D., Martin, T., Nooka, A., Harvey, R. D., Vij, R., Niesvizky, R., et al. (2013). Integrated safety profile of single-agent carfilzomib: Experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica, 98, 1753-1761.
150. Siegel, D. S., Martin, T., Wang, M., Vij, R., Jakubowiak, A. J., Lonial, S., et al. (2012). A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood, 120, 2817-2825.
151. Silva, G. M., Netto, L. E., Discola, K. F., Piassa-Filho, G. M., Pimenta, D. C., Bárcena, J. A., et al. (2008). Role of glutaredoxin 2 and cytosolic thioredoxins in cysteinyl-based redox modification of the 20S proteasome. The FEBS Journal, 275, 2942-2955.
152. Silva, G. M., Netto, L. E., Simões, V., Santos, L. F., Gozzo, F. C., Demasi, M. A., et al. (2012). Redox control of 20S proteasome gating. Antioxidants & Redox Signaling, 16, 1183-1194.
153. Srkalovic, G., Hussein, M. A., Hoering, A., Zonder, J. A., Popplewell, L. L., Trivedi, H., et al. (2014). A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Medicine, 3, 1275-1283.
154. Stella, F., Weich, N., Panero, J., Fantl, D. B., Schutz, N., Fundia, A. F., et al. (2013). Glutathione S-transferase P1 mRNA expression in plasma cell disorders and its correlation with polymorphic variants and clinical outcome. Cancer Epidemiology, 37, 671-674.
155. Stessman, H. A., Baughn, L. B., Sarver, A., Xia, T., Deshpande, R., Mansoor, A., et al. (2013). Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Molecular Cancer Therapeutics, 12, 1140-1150.
156. Stessman, H., Lulla, A., Xia, T., Mitra, A., Harding, T., Mansoor, A., et al. (2014). High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma. Leukemia, 28, 2263-2267.
157. Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Spička, I., Oriol, A., et al. (2015). Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. The New England Journal of Medicine, 372, 142-152.
158. Sui, X., Chen, R., Wang, Z., Huang, Z., Kong, N., Zhang, M., et al. (2013). Autophagy and chemotherapy resistance: A promising therapeutic target for cancer treatment. Cell Death & Disease, 4, e838.
159. Suzuki, K., Ogura, M., Abe, Y., Suzuki, T., Tobinai, K., Ando, K., et al. (2015). Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma. International Journal of Hematology, 101(3), 286-294.
160. Tabe, Y., Sebasigari, D., Jin, L., Rudelius, M., Davies-Hill, T., Miyake, K., et al. (2009). MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clinical Cancer Research, 15, 933-942.
161. Tai, Y. T., Dillon, M., Song, W., Leiba, M., Li, X. F., Burger, P., et al. (2008). Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood, 112, 1329-1337.
162. Tai, Y. T., Mayes, P. A., Acharya, C., Zhong, M. Y., Cea, M., Cagnetta, A., et al. (2014). Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood, 123, 3128-3138.
163. Tew, K. D., & Townsend, D. M. (2011a). Regulatory functions of glutathione S-transferase P1-1 unrelated to detoxification. Drug Metabolism Reviews, 43, 179-193.
164. Tew, K. D., & Townsend, D. M. (2011b). Redox platforms in cancer drug discovery and development. Current Opinion in Chemical Biology, 15, 156-161.
165. Tew, K. D., & Townsend, D. M. (2012). Glutathione-s-transferases as determinants of cell survival and death. Antioxidants & Redox Signaling, 17, 1728-1737.
166. Thieblemont, C., Rolland, D., Baseggio, L., Felman, P., Gazzo, S., Callet-Bauchu, E., et al. (2008). Comprehensive analysis of GST-pi expression in B-cell lymphomas: Correlation with histological subtypes and survival. Leukemia & Lymphoma, 49, 1403-1406.
167. Touzeau, C., Dousset, C., Bodet, L., Gomez-Bougie, P., Bonnaud, S., Moreau, A., et al. (2011). ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents. Clinical Cancer Research, 17, 5973-5981.
168. Trudel, S., Li, Z. H., Rauw, J., Tiedemann, R. E., Wen, X. Y., & Stewart, A. K. (2007). Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood, 109, 5430-5438.
169. Turkson, J., Kim, J. S., Zhang, S., Yuan, J., Huang, M., Glenn, M., et al. (2004). Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Molecular Cancer Therapeutics, 3, 261-269.
170. Udi, J., Sch€uler, J., Wider, D., Ihorst, G., Catusse, J., Waldschmidt, J., et al. (2013). Potent in vitro and in vivo activity of sorafenib in multiple myeloma: Induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization. British Journal of Haematology, 161, 104-116.
171. Usami, H., Kusano, Y., Kumagai, T., Osada, S., Itoh, K., Ko-bayashi, A., et al. (2005). Selective induction of the tumor marker glutathione S-transferase P1 by proteasome inhibitors. The Journal of Biological Chemistry, 280, 25267-25276.
172. van der Veer, M. S., de Weers, M., van Kessel, B., Bakker, J. M., Wittebol, S., Parren, P. W., et al. (2011). The therapeutic human CD38 antibody daratumumab improves the antimyeloma effect of newly emerging multi-drug therapies. Blood Cancer Journal, 1, e41.
173. vanRhee, F.,Szmania, S.M., Dillon,M., vanAbbema, A.M.,Li, X., Stone,M.K., et al. (2009). Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Molecular Cancer Therapeutics, 8, 2616-2624.
174. Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., et al. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 303, 844-848.
175. Verbrugge, S. E., Al, M., Assaraf, Y. G., Niewerth, D., van Meerloo, J., Cloos, J., et al. (2013). Overcoming bortezomib resistance in human B cells by anti-CD20/rituximabmediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Experimental Hematology & Oncology, 2, 2.
176. Verbrugge, S. E., Assaraf, Y. G., Dijkmans, B. A., Scheffer, G. L., Al, M., den Uyl, D., et al. (2012). Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistanceassociated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: Ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. The Journal of Pharmacology and Experimental Therapeutics, 341, 174-182.
177. Vij, R., Savona, M., Siegel, D. S., Kaufman, J. L., Badros, A., Ghobrial, I. M., et al. (2014). Clinical profile of single-agent oprozomib in patients (Pts) with multiple myeloma (MM): Updated results from a multicenter, open-label, dose escalation phase 1b/2 study [abstract]. Blood, 124, 34.
178. Vogl, D. T., Raje, N., Hari, P., Jones, S. S., Supko, J. G., Leone, G., et al. (2014). Phase 1B results of ricolinostat (ACY-1215) combination therapy with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (MM). In ASH annual meeting, Abstract 4764.
179. Vogl, D. T., Stadtmauer, E. A., Tan, K. S., Heitjan, D. F., Davis, L. E., Pontiggia, L., et al. (2014). Combined autophagy and proteasome inhibition: A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy, 10, 1380-1390.
180. Voorhees, P. M., Chen, Q., Kuhn, D. J., Small, G. W., Hunsucker, S. A., Strader, J. S., et al. (2007). Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clinical Cancer Research, 13, 6469-6478.
181. Vousden, K. H., & Prives, C. (2009). Blinded by the light: The growing complexity of p53. Cell, 137, 413-431.
182. Wang, T., Arifoglu, P., Ronai, Z., & Tew, K. D. (2001). Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. The Journal of Biological Chemistry, 276, 20999-21003.
183. Wang, Z. Y., & Chen, Z. (2008). Acute promyelocytic leukemia: From highly fatal to highly curable. Blood, 111, 2505-2515.
184. Wang, X., Yen, J., Kaiser, P., & Huang, L. (2010). Regulation of the 26S proteasome complex during oxidative stress. Science Signaling, 3, ra88.
185. Weber, D. M., Graef, T., Hussein, M., Sobecks, R. M., Schiller, G. J., Lupinacci, L., et al. (2012). Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clinical Lymphoma, Myeloma & Leukemia, 12, 319-324.
186. Wegenka, U. M., Buschmann, J., L€utticken, C., Heinrich, P. C., & Horn, F. (1993). Acutephase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Molecular and Cellular Biology, 13, 276-288.
187. Wen, J., Feng, Y., Huang, W., Chen, H., Liao, B., Rice, L., et al. (2010). Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leukemia Research, 34, 85-92.
188. Wuillème-Toumi, S., Robillard, N., Gomez, P., Moreau, P., Le Gouill, S., Avet-Loiseau, H., et al. (2005). Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia, 19, 1248-1252.
189. Yan, H., Wang, Y. C., Li, D., Wang, Y., Liu, W., Wu, Y. L., et al. (2007). Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: The role of protein kinase Cdelta. Leukemia, 21, 1488-1495.
190. Yin, L., Kufe, T., Avigan, D., & Kufe, D. (2014). Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death. Blood, 123, 2997-3006.
191. Yu, C., Rahmani, M., Dent, P., & Grant, S. (2004). The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Experimental Cell Research, 295, 555-566.
192. Zhong, Z., Wen, Z., & Darnell, J. E., Jr. (1994). Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science, 264, 95-98.
193. Zmijewski, J. W., Banerjee, S., & Abraham, E. (2009). S-glutathionylation of the Rpn2 regulatory subunit inhibits 26 S proteasomal function. The Journal of Biological Chemistry, 284, 22213-22221.